| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Semaglutide in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta-analysis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Maneeth Mylavarapu, Ogechukwu Obi, Yozahandy Abarca, Husna Fatima, Prarath Roshni, Noor Ul Huda, Yuliya Lysak, Asad Gandapur, Samantha Contreras Vazquez, Muhammad Areeb Siddiqui and Adetola Mowo-Wale |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Maneeth Mylavarapu, Department of Cardiology, Endeavor Health Cardiovascular Institute, 2100 Pfingsten Rd, Glenview, IL 60026, United States, Glenview, IL 60026, United States. dr.maneeth.mylavarapu@gmail.com |
| Key Words |
Semaglutide; Heart failure with preserved ejection fraction; Obesity; Weight-loss; GLP-1 receptor agonists; Meta-analysis |
| Core Tip |
This meta-analysis demonstrates that semaglutide is effective in reducing weight and potentially lowering the risk of heart failure events in patients with obesity and heart failure with preserved ejection fraction (HFpEF). This suggests semaglutide as a promising therapeutic option for managing obesity-related HFpEF, a condition with limited current treatment options. The findings showed statistically higher odds of 10% and 15% weight reduction, as well as lower odds of adjudicated heart failure events, in patients receiving semaglutide compared to those receiving placebo. Further large-scale trials are needed to confirm these benefits and explore long-term outcomes. |
| Publish Date |
2026-03-23 08:54 |
| Citation |
Mylavarapu M, Obi O, Abarca Y, Fatima H, Roshni P, Huda NU, Lysak Y, Gandapur A, Vazquez SC, Siddiqui MA, Mowo-Wale A. Semaglutide in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta-analysis. World J Cardiol 2026; 18(3): 112189 |
| URL |
https://www.wjgnet.com/1949-8462/full/v18/i3/112189.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v18.i3.112189 |
